Truly Differentiated Therapeutics
from
Biology-First AI Platform
First patient in Asia receives AU409 following the ongoing first-in-human clinical trial in the US for liver cancer
READ MORE >>
First patient in Asia receives AU409 following the ongoing first-in-human clinical trial in the US for liver cancer READ MORE >>
MEET AURANSA
We are a clinical stage, AI-native biopharma with a proprietary AI platform that harnesses available human disease data to discover novel therapeutics and raise the standard of cancer care.
Our AI platform
harnesses abundant, available and heterogeneous human disease data to discover novel therapies for the most responsive patients
Diseases crunched from 500,000+ gene expression profiles, now advancing to studies in liver cancer, heart-safe chemotherapy, and more
“As an early pioneer in genomics technology, first at Rosetta and later at Merck, I’ve long been a champion of the integration of data science into biological discovery. I am most excited by the next chapter; Auransa and the intersection of AI, biology, massive data, and precision medicine.”
Pek Lum, Co-Founder and CEO, Auransa
